瑞舒伐他汀对冠心病患者内皮功能的影响研究  

Effect of Atorvastatin on Endothelial Function in Patients with Coronary Heart Disease

作　　者：黄小云[1] 韦建瑞[2] 

机构地区：[1]华南农业大学医院,广东广州510642 [2]广州市红十字会医院,广东广州510220

出　　处：《临床医学工程》2016年第1期48-49,共2页Clinical Medicine & Engineering

摘　　要：目的研究瑞舒伐他汀对冠心病患者内皮功能的影响。方法将121例冠心病患者随机分为对照组62例和研究组59例,所有患者均给予冠心病常规治疗,研究组在此基础上给予瑞舒伐他汀,于治疗前、治疗后4周检测患者的一氧化碳(NO)、一氧化碳合酶(NOS)、非对称二甲基精氨酸、e NOS m RNA相对表达量及肱动脉流量介导的舒张功能(FMD)。结果研究组患者服用瑞舒伐他汀4周后FMD百分率较治疗前提高(2.44±0.11)%,e NOSm/GAPDH灰度值提高0.25±0.05,血清NO、NOS含量较治疗前明显升高,ADMA含量较治疗前明显降低;同时,两组治疗后各项指标比较差异均有统计学意义(P<0.05)。结论瑞舒伐他汀通过可增加NO的分泌,提高利用度,减少脂质沉积,影响内皮功能达到治疗冠心病的作用。Objective To study the effect of atorvastatin on endothelial function in patients with coronary heart disease. Methods 121 patients with coronary heart disease were randomly divided into two groups. 62 cases of control group received routine therapy, while 59 cases of study group were given atorvastatin on the basis of routine therapy. Before treatment and 4 weeks after treatment, the NO, NOS,asymmetric dimethylarginine, relative expression of e NOS m RNA, and brachial artery flow mediated dilation function（FMD） were detected.Results After 4 weeks, the percentage of FMD in the study group increased by（2.44 ± 0.11） %, the e NOSm/GAPDH gray value increased by 0.25 ± 0.05, the serum levels of NO and NOS were significantly higher than those before treatment, and the content of ADMA was significantly lower than that before treatment; All the differences were statistically significant（P〈0.05）. All the indicators 4 weeks after treatment showed statistically significant difference between two groups（P〈0.05）. Conclusions Atorvastatin can increase the secretion of NO, improve the utilization of lipid deposition, and affect the endothelial function, so as to treat coronary heart disease.

关 键 词：瑞舒伐他汀 冠心病 一氧化碳合酶 内皮功能 影响 

分 类 号：R541.4[医药卫生—心血管疾病]